Keyword: Sofinnova Ventures
XyloCor Therapeutics will move its lead asset, a gene therapy for chronic angina, into the clinic in 2019.
The Boston-based biotech unveiled the series A round alongside the appointment of a Spark Therapeutics co-founder and other organizational changes.
The series C sets Amplyx up to take its lead broad-spectrum antifungal candidate into phase 2 later this year.
Iterum has completed a $65 million series B to equip it to take its antibiotic sulopenem through phase 3.
Antiva Biosciences has secured $22 million in a Series C funding round, a week after kick-starting its phase 1 study in healthy women, as it aims to create a new treatment for precancerous lesions caused by human papillomavirus infection.
Quiet upstart BioClin Therapeutics has raised $30 million in a Series B funding round, taking its total to $59 million since its founding, as it aims to push on with clinical work on its bladder cancer candidate B-701 that includes a combo test with Roche’s new PD-L1 med.
Perennial life science investors Atlas and Sofinnova have co-led a $35 million startup funding round for Delinia, a newly emerged biotech that starts life with designs on “rebalancing the immune system” to help treat autoimmune diseases.
Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has announced a pooling of $595 million as its latest investor effort.